Rachel Waters
University of Oxford
Quality of lifeCancerInternal medicineUrologySurgeryPathologyOncologyRandomized controlled trialPhysical therapyIntention-to-treat analysisHazard ratioSurvival rateChemotherapyFollicular lymphomaPenisCisplatinLymphomaBladder cancerFluorouracilDocetaxelRadiation therapyClinical trialMedicineBiologyGastroenterology
Publications 31
#1Mohammad Ali Mansournia (Tehran University of Medical Sciences)H-Index: 38
#2Rachel Waters (University of Oxford)H-Index: 14
Last. Douglas G. Altman (University of Oxford)H-Index: 268
view all 5 authors...
Abstract Introduced in 1983, Bland-Altman methods is now considered the standard approach for assessment of agreement between two methods of measurement. The method is widely used by researchers in various disciplines so that the Bland-Altman 1986 Lancet paper has been named as the 29th mostly highly cited paper ever, over all fields. However, two papers by Hopkins (2004) and Krouwer (2007) questioned the validity of the Bland-Altman analysis. We review the points of critical papers and provide ...
#1Fiona McDonald (The Royal Marsden NHS Foundation Trust)H-Index: 20
#2Rachel WatersH-Index: 14
Last. Robert Huddart (The Royal Marsden NHS Foundation Trust)H-Index: 83
view all 6 authors...
Abstract Aims Increases to radiotherapy dose are constrained by normal tissue effects. The relationship between bowel dose volume data and late bowel toxicity in patients with muscle-invasive bladder cancer treated with radical radiotherapy was assessed. Materials and methods The bowel was contoured retrospectively on radiotherapy plans of 47 patients recruited to the BC2001 trial (CRUK/01/004). The relationship between bowel volume at various dose levels and prospectively collected late bowel t...
13 CitationsSource
#1Jane M BlazebyH-Index: 83
#2Emma HallH-Index: 57
Last. Peter Fayers (Aberd.: University of Aberdeen)H-Index: 79
view all 7 authors...
Background Well-developed and well-tested patient-reported outcome measures for non–muscle-invasive bladder cancer (NMIBC) are required.
36 CitationsSource
#1Ama Z.S. Rohatiner (St Bartholomew's Hospital)H-Index: 42
#2Matthew L. Smith (St Bartholomew's Hospital)H-Index: 12
Last. Andrew Lister (St Bartholomew's Hospital)H-Index: 22
view all 17 authors...
4 CitationsSource
#1Emma Hall (ICR: Institute of Cancer Research)H-Index: 57
#2David Cameron (ECRC: Edinburgh Cancer Research Centre)H-Index: 91
Last. Tact Trial InvestigatorsH-Index: 1
view all 9 authors...
Abstract Background The TACT trial (CRUK/01/001) compared adjuvant sequential FEC-docetaxel (FEC-D) chemotherapy with standard anthracycline-based chemotherapy of similar duration in women with early breast cancer. Results at a median of 5years suggested no improvement in disease-free survival with FEC-D. Given differing toxicity profiles of the regimens, the impact on quality of life (QL) was explored. Methods Patients from 44 centres completed standardised QL questionnaires before chemotherapy...
25 CitationsSource
#1Robert HuddartH-Index: 83
#2Emma HallH-Index: 57
Last. N.D. JamesH-Index: 4
view all 14 authors...
#1Andrew Weaver (University of Oxford)H-Index: 9
#2Sharon Love (University of Oxford)H-Index: 52
Last. Lionel Tarassenko (University of Oxford)H-Index: 66
view all 11 authors...
Purpose Real-time symptom monitoring using a mobile phone is potentially advantageous for patients receiving oral chemotherapy. We therefore conducted a pilot study of patient dose adaptation using mobile phone monitoring of specific symptoms to investigate relative dose intensity of capecitabine, level of toxicity and perceived supportive care.
16 CitationsSource
#1R. HuddartH-Index: 2
Last. Nicholas D. JamesH-Index: 66
view all 13 authors...
#1S. Nicholson (Imperial College Healthcare)H-Index: 1
#2Emma Hall (ICR: Institute of Cancer Research)H-Index: 57
Last. Amit BahlH-Index: 24
view all 13 authors...
Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)
58 CitationsSource
#1Robert HuddartH-Index: 83
#2Emma HallH-Index: 57
Last. Nicholas D. James (University of Birmingham)H-Index: 66
view all 14 authors...
Purpose To test whether reducing radiation dose to uninvolved bladder while maintaining dose to the tumor would reduce side effects without impairing local control in the treatment of muscle-invasive bladder cancer. Methods and Materials In this phase III multicenter trial, 219 patients were randomized to standard whole-bladder radiation therapy (sRT) or reduced high-dose volume radiation therapy (RHDVRT) that aimed to deliver full radiation dose to the tumor and 80% of maximum dose to the uninv...
67 CitationsSource